article: Variation in steroid hormone levels has wide implications for health and disease. The genes encoding the proteins involved in steroid disposition represent key determinants of interindividual variation in steroid levels and ultimately, their effects. Beginning with metabolomic data from genome-wide association studies (GWAS), we observed that genetic variants in the orphan transporter, SLC22A24 were significantly associated with levels of androsterone glucuronide and etiocholanolone glucuronide (sentinel SNPs p-value <1x10-30). In cells over-expressing human or various mammalian orthologs of SLC22A24, we showed that steroid conjugates and bile acids were substrates of the transporter. Phylogenetic, genomic, and transcriptomic analyses suggested that SLC22A24 has a specialized role in the kidney and appears to function in the reabsorption of organic anions, and in particular, anionic steroids. Phenome-wide analysis showed that functional variants of SLC22A24 are associated with human disease such as cardiovascular diseases and acne, which have been linked to dysregulated steroid metabolism. Collectively, these functional genomic studies reveal a previously uncharacterized protein involved in steroid homeostasis, opening up new possibilities for SLC22A24 as a pharmacological target for regulating steroid levels.
  Steroid hormones represent major signaling molecules and have been the subject of numerous investigations[1]. Precise regulation of steroid levels is important for human health and disease, which has stimulated many studies focused on the identification and characterization of the genes, proteins, and pathways involved in steroid metabolism and disposition. In addition, genome-wide association studies (GWAS) have been performed to identify the polymorphisms that associate with interindividual variation in the levels of steroids, and to discover additional genes that are involved in steroid disposition. In general, multiple GWAS have led to the identification of genes already known to be involved in steroid metabolism, binding and regulation [2–7]. However, one locus, SLC22A24, has puzzled researchers because it has no known role in steroid homeostasis [6,8, 9]. SLC22A24 encodes an orphan solute carrier (SLC) transporter which has no currently known ligands. The human solute carrier (SLC) transporter superfamily includes approximately 400 proteins grouped into 52 families [10–13]. SLC22A24, an orphan transporter, belongs to the SLC22 family, which transports organic ions [14]. In the human genome, the SLC22 family includes 22 members and represents the third largest in the SLC transporterome, behind SLC25 and SLC35 families. The first human member of this family was cloned and characterized in 1997 [15,16], and since then, members of the family were shown to play critical pharmacological roles in mediating the hepatic and renal elimination of a variety of endogenous compounds and drugs (e. g. , SLC22A1 encoding organic cation transporter 1 (OCT1), SLC22A2 encoding OCT2, SLC22A6 encoding organic anion transporter 1 (OAT1), and SLC22A8 encoding OAT3) [17,18]. Because of their important pharmacologic role, many members of the SLC22 family are recognized as important determinants of drug disposition and mediators of drug-drug interactions [17], and are frequently studied during drug development [12]. In spite of the increasing recognition as playing key roles in drug response and toxicity, and indeed in human physiology and pathophysiology, the SLC22 family still contains a large cluster of orphan transporters, including SLC22A10, SLC22A14, SLC22A15, SLC22A17, SLC22A18, SLC22A23, SLC22A24, SLC22A25, and SLC22A31 [19,20]. In fact, close to 75 members of the human SLC superfamily remain classified as orphan transporters, i. e. , they have no assigned ligands [10,11,21]. A number of factors appear to contribute to this paradox including a non-unified nomenclature and technical challenges involved in working with membrane proteins[11]. SLCs that have been characterized to date function in the transmembrane flux of solutes, which include inorganic ions, such as heavy metals, as well as organic compounds, such as neurotransmitters and amino acids. Therefore, the key step in understanding the physiological role of these proteins is identifying their endogenous substrates. Over the years, various functional and molecular approaches have been employed to identify the endogenous ligands of SLC transporters. One robust approach for the identification of substrates has been the use of genome-wide association studies (GWAS) to identify single nucleotide polymorphisms (SNPs) in SLCs that associate with circulating levels of various metabolites. For example, the discovery of GLUT9 (encoded by SLC2A9) as a uric acid transporter stemmed from a GWAS focused on the identification of genetic variants associated with hyperuricemia and gout [22,23]. Further, the characterization of SLC16A9 as a carnitine efflux transporter was motivated by a GWAS with metabolomics [24]. Also, tetradecanedioic acid and hexadecanedioic acid were discovered to be naturally occurring substrates of OATP1B1 (encoded by SLCO1B1) in a GWAS aimed at identifying metabolomic biomarkers for the transporter [25,26]. In this study, we used a combination of computational and experimental approaches to uncover endogenous ligands and substrates of SLC22A24. These approaches included radiolabeled substrate and inhibition screens, metabolomic profiling of cells over-expressing SLC22A24, and sequence and structure-based analyses. To provide further support for the endogenous role of the human SLC22A24, we profiled its expression levels in various tissues and cell types. Phylogenetic analysis revealed that the transporter has orthologs in primates and a few other mammalian species, suggesting a specialized role of the transporter. Our work also implicates the transporter in the disposition of drugs and drug metabolites with a steroid scaffold. To our knowledge, this is the first study to identify endogenous and pharmacological substrates of SLC22A24. Further studies are warranted to understand the complete physiological and pharmacological roles of the transporter in human and primate biology.
  Three independent GWAS reveal strong associations of SNPs in SLC22A24 with steroid levels. In particular, the metabolites that reached genome-wide significance included progesterone (p<10−11) [6], androsterone glucuronide (sentinel SNP p<10−50) [8,9], and etiocholanolone glucuronide (sentinel SNP p<10−30) [8]. A locus zoom plot shows the significance pattern of SNPs in and around SLC22A24 for the association with androsterone glucuronide (Fig 1A), etiocholanolone glucuronide (Fig 1B) and pregnanediol-3-glucuronide (Fig 1C). The SNPs in the vicinity of SLC22A24 have the most significant associations with androsterone glucuronide and etiocholanolone glucuronide in GWAS [8,9]. The top SNPs for progesterone (rs112295236) and the sentinel SNPs for androsterone glucuronide and etiocholanolone glucuronide (rs78176967, rs151042642) [6,8, 9] are in the region between SLC22A24 and SLC22A8. These SNPs are in strong linkage disequilibrium (LD), r2>0. 8, to SNPs within SLC22A24 (Fig 1A and 1B). Interestingly, a nonsense variant in SLC22A24 (rs11231341, Tyr501Ter, c. 1503T>G), is strongly associated with the levels of androsterone glucuronide and etiocholanolone glucuronide (p<5x10-8) (Fig 1A and 1B). Using LDLink[27], we identified the SNPs in linkage with rs78176967 and rs151042642, and found that among the missense, nonsense, or splice donor variants in SLC22A24 (rs11231341, rs7945121, rs1939749), SLC22A25 (rs6591771) and SLC22A10 (rs1790218, rs1201559), the SLC22A24 p. Tyr501Ter (rs11231341) has the strongest correlation to the top SNPs associated with the steroid glucuronides, with r2 = 0. 22, D’ = 1. 0 (Fig 1D). In addition to the published data, we used data from the Atherosclerosis Risk in Communities Study (ARIC) to confirm the direction of the association of the nonsense variant, SLC22A24 p. Tyr501Ter, with plasma levels of the two metabolites. In particular, this independent cohort consists of 1,375 Caucasians and 573 African Americans with available genotype data and steroid metabolite levels. Primary analysis showed that the major allele (G-allele), encoding the nonsense variant SLC22A24 p. Tyr501Ter, is associated with lower plasma levels of the two steroid glucuronide conjugates, androsterone glucuronide and etiocholanolone glucuronide (Fig 1E, Table 1). Further, association analysis in ARIC study also confirmed weaker associations of other missense variants or nonsense variants in SLC22A25 and SLC22A10 (S2 Table). We were puzzled by the observation that the sentinel SNPs, rs78176967 and rs151042642, exhibited stronger associations with steroid levels (p-values range from 1x10-55 to 9x10-11) than the nonsense SNP, rs11231341 (encoding p. Tyr501Ter, p-values range from 0. 0014–1x10-13) (Table 2). As the sentinel SNPs, rs78176967 and rs151042642, are intergenic variants with no known or predicted cis-regulatory effects, we suspected that they may tag true causal variants that are linked to them in addition to rs11231341. Searching for publicly available eQTL, we noted that the splice donor variant in SLC22A24, rs1939749, is the top SNP for associations with SLC22A24 transcript levels in kidney eQTL databases[28–30] (S1 Fig). In particular, rs1939749 resides at the 3’ junction of exon 1 and could affect splicing between exons 1 and 2. Incorrect splicing at the 3’ junction of exon 1, i. e. , with the minor allele variant, would result in a premature stop codon (S1 Fig). We hypothesized that rs1939749 drives the SLC22A24 expression levels and thus the minor allele results in lower transcript levels (S1 Fig). Interestingly, the minor alleles (A-alleles) of the sentinel SNPs (rs78176967 and rs151042642) are in complete linkage disequilibrium (D’ = 1) with the major allele (G-allele) of rs1939749 and the minor allele (T-allele) of rs11231341 encoding Tyr501 (Fig 1F). The resultant haplotype, rs78176967: rs151042642: rs11231341: rs1939749 = A: A: T: G, which is present at ~5% haplotype frequency, is expected to retain function as there is no stop codon present at position 501 (T-allele) and no defective splicing (G-allele). The weaker p-value of the allele encoding Tyr501, rs11231341, is due to the fact that it may occur in two distinct haplotypes, one that is a loss of function due to the allele that is predicted to disrupt splicing (rs1939749), and one that retains function (no splicing defect) (Fig 1F). Overall, these results led to further studies designed to explore the functional role of SLC22A24 as a transporter of steroids and steroid conjugates. We performed an uptake screen of 21 radiolabeled canonical substrates of various SLC22 family members, spanning cations, anions, and zwitterions. The experiments confirmed that SLC22A24 is a transporter of select organic anions (S4 Table). Cells transiently transfected with SLC22A24 accumulated steroid anionic compounds, including [3H]-taurocholic acid (TA) (10–20 fold over empty vector control), [3H]-glycocholic acid (GA) (10–20 fold), [3H]-estrone sulfate (ES) (5–10 fold), [3H]-estradiol-17β-glucuronide (EG) (3–5 fold), and [3H]-androstanediol glucuronide (AG) (5–15 fold) (Fig 3A). The uptakes of [3H]-estrone sulfate, [3H]-estradiol-17β-D-glucuronide, [3H]-androstanediol glucuronide, [3H]-taurocholic acid and [3H]-glycocholic acid were time dependent, reaching plateaus at approximately 5 min (S2 Fig). Kinetic parameters were evaluated at 1 min, except the uptake rate of taurocholic acid, which was evaluated at 2 min. The uptake kinetics of [3H]-estrone sulfate, [3H]-estradiol-17β-D-glucuronide, [3H]-taurocholic acid, and [3H]-glycocholic acid exhibited saturable characteristics at higher concentrations, with Km values (mean ± SD) of 8. 6 ± 0. 3 μM, 17. 5 ± 0. 2 μM, 10. 5 ± 1. 1 μM, and 33. 4 ± 2. 5 μM, respectively (Fig 3B, S5 Table). Similar values were observed for SLC22A8 (S5 Table). The kinetic parameters of androstanediol-3-glucuronide could not be determined accurately in SLC22A24 expressing cells due to a solubility limit of 300 μM (S3 Fig). Using the plateau at 300 μM as an approximation, the Km of androstanediol glucuronide for SLC22A24 was estimated to be 741 ± 253 μM, which is higher than for SLC22A8. Next, we characterized the uptake of monocarboxylic and dicarboxylic acid derivatives, which are known substrates of other anion transporters, including several prescription drugs. Among the compounds that were identified as substrates of SLC22A24, two were dicarboxylic acids (i. e. succinic acid and 6-carboxyfluorescein, 6-CF) and two were monocarboxylic acids (i. e. 4’, 5’-dibromofluorescein, DBF, and 2’7’-dichlorofluorescein, DCF) (Fig 3C). However, other anion substrates of SLC22A6, SLC22A7, or SLC22A8, were determined not to be substrates of SLC22A24. Those include para-aminohippuric acid (PAH), uric acid, orotic acid, alpha-ketoglutaric acid and tetradecanedioic acid (S4 Table). The prescription drug, methotrexate, and the mycotoxin, ochratoxin A, showed significant uptake by SLC22A24 expressing over EV cells (Fig 3D), whereas tenofovir and adefovir, which have phosphate moieties, were not substrates of the transporter (S4 Table). Further, none of the tested cationic and zwitterionic substrates of SLC22A1-SLC22A5 showed significant (>1. 5 fold) accumulation in SLC22A24 expressing cells compared to EV cells (S4 Table). Collectively, the data indicate that SLC22A24 transports various organic anions, including steroid compounds with anionic moieties (sulfates, carboxylic acids, glucuronides) and non-steroid compounds with dicarboxylic acid moieties. We examined the underlying transport mechanism of SLC22A24 in order to determine whether it relies on facilitative diffusion or on secondary active transport of ions. Uptake of [3H]-estrone sulfate was not affected by pH between 5. 5 to 8. 5 and was not dependent on the presence of Na+ ions (S4 Fig). However, uptake of [3H]-estrone sulfate, as well as that of other steroid conjugates, was significantly affected by the presence of Cl- ions. Cl-free buffer nearly doubled the uptake of all tested compounds (Fig 3E). In addition, we tested trans-stimulation of SLC22A24-mediated uptake by preloading the cells with succinic acid, alpha-ketoglutaric acid, and glutaric acid, which are known to trans-stimulate other organic anion transporters [37–39]. Among the three, only glutaric acid significantly increased the uptake of [3H]-estrone sulfate, [3H]-estradiol glucuronide, [3H]-androstanediol glucuronide, and [3H]-taurocholic acid (Fig 3F). The primary goal of the inhibition studies was to confirm that solutes identified in the metabolomic studies were ligands of SLC22A24 and to identify additional ligands of the transporter. The secondary goal was to determine whether known inhibitors of other organic anion transporters in the SLC22 family were inhibitors of SLC22A24. A total of 85 compounds were selected for inhibition studies of SLC22A24-mediated [3H]-taurocholic acid uptake (S6 Table, Fig 4A). These included: (i) 4 steroid metabolites identified in GWAS at p<1x10-6; (ii) 20 known inhibitors or substrates of other organic anion transporters; (iii) 17 steroids or bile acids which are used clinically; (iv) 8 dicarboxylic acid metabolites identified in our metabolomic study; and (v) 20 steroid conjugates. At 100 μM, 43 of the 86 test-compounds inhibited the SLC22A24-mediated [3H]-taurocholic acid uptake by >50%. All 16 bile acids, 5 of the 15 unconjugated steroids, 15 of the 20 steroid conjugates, and 12 of the 22 other anionic non-steroidal compounds inhibited taurocholic acid uptake by >50% (Fig 4A, S6 Table). Many sulfate conjugates including steroid sulfates inhibited taurocholic acid uptake. Some non-steroidal compounds known to inhibit organic anion transporters also inhibited SLC22A24-mediated taurocholic acid uptake potently (e. g. losartan, rosiglitazone, lesinurad, benzbromarone) or partially (e. g. probenecid, bumetanide, ketoprofen). Three steroid metabolites identified in the GWAS, progesterone, androsterone glucuronide, and etiocholanolone glucuronide inhibited taurocholic acid uptake >50%. Consistent with these results, SNPs in SLC22A24 were associated with progesterone, androsterone glucuronide and etiocholanolone glucuronide at genome-wide significance levels (p<5x10-8), whereas associations were weaker for pregnanediol-3-glucuronide (p = 2x10-7), which was a weaker inhibitor of SLC22A24-mediated taurocholic acid uptake (Fig 4A) [8]. At a high concentration (1 mM), five of the nine dicarboxylic acids inhibited taurocholic acid uptake by approximately 50% (Fig 4A). However, UDP-glucuronate and N-acetylasparagine did not inhibit taurocholic acid uptake even at 1 mM. Ten compounds were selected for further IC50 studies (Table 3). We specifically focused on the steroids and steroid conjugates reported in GWAS and the steroid conjugates with the strongest inhibition in the initial screen. Two bile acids, chenodeoxycholic acid and ursodeoxycholic acid, were selected because they are used clinically to treat gallstone and related cholestatic liver disease [40,41]. Two non-steroidal drugs, rosiglitazone and lesinurad, were selected because of their strong inhibition in the initial screen. Pregnenolone sulfate, chenodeoxycholic acid, and rosiglitazone exhibited potent IC50 values (IC50 < 5 μM) (Fig 4B). Progesterone, ursodeoxycholic acid, and lesinurad were also inhibitors with IC50 < 20 μM. Finally, the three steroid glucuronide conjugates, androsterone glucuronide, etiocholanolone glucuronide, and androstanediol-3-glucuronide, achieved IC50 values for inhibition of SLC22A24-mediated taurocholic acid uptake of 45 ± 29 μM, 57 ± 36 μM and 21 ± 11 μM, respectively (Table 3). The IC50 values of androsterone glucuronide and etiocholanolone glucuronide are relatively similar to the reported concentrations of these metabolites in the urine (ranges from 1–33 μM for androsterone glucuronide and 0. 9–20. 4 μM for etiocholanolone glucuronide) [42,43]. According to UniProt, Ensembl, and NCBI RefSeq, the SLC22A24 transcript is identified in three major isoforms. Specifically, ENST00000612278. 4 (552 amino acids, NM_001136506, A0A087WWM3), identified in this paper as the reference SLC22A24, ENST00000417740. 5 (551 amino acids, no known NCBI reference, C9JC66), identified as SLC22A24-551, and ENST00000326192. 5 (322 amino acids, NM_173586, Q8N4F4), identified as SLC22A24-322. The short SLC22A24-322 isoform was omitted from further analysis due to its lack of transport activity, expression from GFP fusion construct, and absence of key structural motifs (see S7 Fig). Transcripts of the two isoforms (SLC22A24 and SLC22A24-551) were detected using PCR and the sequences were confirmed. The SLC22A24-551 isoform exists due to the presence of two potential AG acceptor sites at the splice junction between exons 9 and 10, (indicated as position “1” or “2” on S8A Fig), thus resulting in two different splice variants. The splice variants differ in two amino acids in position 533 and 534 (S8B Fig). Functional characterization of SLC22A24 and SLC22A24-551 indicated no significant differences in their uptake function. In particular, a similar fold-uptake over control between the two isoforms was observed for all representative steroid glucuronides, steroid sulfates, bile acids, methotrexate and succinic acid (Fig 6A). Next, we characterized the nonsense variant in SLC22A24, which is associated at genome-wide significance levels with androsterone glucuronide and etiocholanolone glucuronide (Fig 1). A survey of the 1000 Genomes Project Phase 3, revealed that the G-allele of rs11231341, coding for p. Tyr501Ter, is the major allele, ranging from 51% in Mende in Sierra Leone to 92% in Peruvian in Lima, Peru [48]. In addition, the G-allele is the major allele (80%) in individuals from the Greater Middle East (GME) (The GME Variome Project, http: //igm. ucsd. edu/gme/). Cells transiently transfected with SLC22A24 p. Tyr501Ter exhibited no transport function (Fig 6B). Consistent with the uptake studies, GFP-tagged SLC22A24 localized to the membrane, while GFP-tagged SLC22A24 p. Tyr501Ter did not (Fig 6C). Further, plasma membrane protein expression was evaluated using Western blots for HEK293 Flp-In cells stably expressing SLC22A24 or transiently transfected with either empty vector only (EV, pCMV6-Entry), SLC22A24, or SLC22A24 p. Tyr501Ter (S9 Fig). All samples expressed the positive control, Na+/K+-ATPase. SLC22A24 was expressed in both the stable cell sample as well as the transiently transfected cells. SLC22A24 p. Tyr501Ter was not detected on the plasma membrane of the transiently transfected cells, despite having detectable mRNA levels (S9 Fig).
  Steroids including sex steroids and glucocorticosteroids have pleiotropic actions in reproductive and other tissues in the body and impact numerous biological processes [1,53,54]. In particular, they influence body composition, glucose and lipid metabolism, cardiovascular and immunological functions, and reproductive fitness [54]. Accordingly, there is a vast literature focused on the study of the action, regulation, metabolism and disposition of steroids [1]. GWAS have revealed a number of genes that are involved in steroid metabolism and hormone binding as the major determinants of interindividual variation in the levels of many steroids and steroid conjugates [2–7,55]. Intrigued by the association of a novel locus and an orphan transporter, SLC22A24, with metabolite levels in metabolomic GWAS, we performed experimental studies along with a computational analysis to functionally characterize the transporter and further understand its physiological role. Our studies led to four major findings. First, SLC22A24 is an organic anion transporter, consistent with multiple GWAS focused on metabolites, and validated through comparative structure models, cell-based metabolomic screens, and functional studies. Second, SLC22A24 is conserved among higher order primates, but has diverged within lower level primates and other mammals. Third, two functional isoforms of SLC22A24 are detectable in the human kidney, and the transporter has a highly specific expression pattern in the nephron, localized to segment 3 of the proximal tubule. Fourth, the transporter has a common nonsense variant, p. Tyr501Ter (rs11231341), which is found at high allele frequencies in human populations, and is associated with low steroid and steroid conjugate levels (p<5x10-8). Below we discuss each of the major findings in detail. The first major finding of the study is that SLC22A24 is an organic anion transporter (Figs 2 and 3). Based on results the GWAS (Fig 1), metabolomic profiling and comparative structure modeling (Fig 2), we hypothesized and validated in our in vitro and cellular metabolomic studies that SLC22A24 preferentially transports organic anions. However, it does not transport a number of organic anions transported by other organic anion transporters in the SLC22 family (SLC22A6, SLC22A7 and SLC22A8). For example, we did not detect transport of uric acid, tenofovir, cGMP, or alpha-ketoglutaric acid, which are canonical substrates of SLC22 organic anion transporters (S5 Table) [20,56]. Further, our results showed that SLC22A24 is Cl-dependent (Fig 3E). A similar chloride dependency has been observed for URAT1 (SLC22A12), a major uric acid reabsorptive transporter in the kidney [57], and OAT4 (SLC22A11), which uses the downhill flux of chloride ions to move its organic anion substrates across the apical membrane of the renal proximal tubule [37,58]. Similar to OAT1 (SLC22A6), OAT3 (SLC22A8) and OAT4 (SLC22A11), SLC22A24 was also trans-stimulated by glutaric acid [37,38,59,60], but not significantly by succinic acid and alpha-ketoglutaric acid (Fig 3F). In contrast, OAT1 and OAT3 are trans-stimulated by alpha-ketoglutaric acid as well as glutarate, consistent with a broader selectivity of these two transporters in comparison to SLC22A24. Our second finding is that many species, including lower level primates and rodents, do not have orthologs of SLC22A24. Phylogenetic analysis reveals the presence of SLC22A24 orthologs in apes, lemur, and certain other mammalian species, but none in rodents. Human SLC22A24, located on chromosome 11q12, falls within a cluster of other SLC22 family genes called the Unknown Substrate Transporters (USTs), consisting of SLC22A9, SLC22A10, and SLC22A25. Sequence comparison indicates that human SLC22A24 is distant from those in mice and rats (mouse USTs include Slc22a26, a27, a28, a29, a30, a9/a19; rat USTs include Slc22a9/a24, a9/a25, Ust4r, Ust5r) (Fig 5A, S5 Fig) and only 11 species have direct orthologs of the human SLC22A24 (see ref. [46], Ensembl database (version 95) ). Previous studies have characterized the function of human liver specific SLC22A9 (OAT7) [25], several rodent USTs, including the rat kidney Slc22a9/a24 (Oat5) [61], rat kidney Slc22a9/a25 (Ustr1/Oat8) [62,63], mouse kidney Slc22a9/a19 (Oat5) [64–66], and mouse liver and kidney Slc22a30 (Oat9) [67]. All of the above transporters transport steroid sulfate conjugates and some other anions, such as ochratoxin A. However, they do not transport and are not inhibited by steroid glucuronide conjugates, which are substrates and inhibitors of the human SLC22A24 [61,63]. Consistent with these results, steroid glucuronides are not detectable in rat urine but are detectable in human urine [68]. Further, glucuronidated steroids are not detected in serum samples from rodents [69]. Our third finding is that the functional isoforms of the human SLC22A24, are expressed at lower levels in kidney and liver tissues compared to other known kidney-specific anion transporters from the SLC22 family, e. g. , SLC22A6, SLC22A8, SLC22A11, and SLC22A12, as noted from the RNA-seq data generated by the Human Protein Atlas (HPA) [70] and the Genotype-Tissue Expression (GTEx) consortium (see S10 Table). Though expressed at lower levels, the primary finding that genetic variants in SLC22A24 associate with plasma levels of several metabolites (S1 Table), suggests that the transporter plays a critical and specific role in determining systemic levels of metabolites. The narrower substrate selectivity of SLC22A24 as compared to other SLC22 organic anion transporters, SLC22A6 and SLC22A8, which are broadly selective, further supports a specific role for the transporter in the kidney. The Kidney Interactive Transcriptomics database (http: //humphreyslab. com/SingleCell/search. php) shows SLC22A24 to be expressed specifically in S3 (Fig 7B) and not in the other regions of the human kidney, which suggests that SLC22A24 plays a specific role in the kidney in comparison with other renal organic anion transporters in the SLC22 family. The selective localization of SLC22A24 in the human kidney is consistent with the renal localization of rodent USTs, which are expressed in particular sub-regions of the kidney [61,63,65]. For example, rat Slc22a9 is expressed on the apical membrane of the collecting duct [63], and mouse Slc22a9/a19 is expressed on the apical membrane of the proximal tubules of the outer medulla [61,65]. Collectively, the data suggest a specific role for SLC22A24 in the kidney, reminiscent of USTs in rodents, which do not express SLC22A24. Our fourth finding is that the transporter has a common nonsense variant, p. Tyr501Ter (rs11231341), which is found at high allele frequencies in human populations, and is a major determinant of inter-individual variation in plasma levels of certain steroid and steroid conjugates (p<5x10-8). Premature stop codons sometimes trigger nonsense-mediated decay (NMD), which in this case might cause a rapid degradation of the SLC22A24 transcripts and result in the observed lack of detectable protein signal in the kidney samples from individuals who are homozygous for p. Tyr501Ter (S8 Table). The overall low mRNA transcript levels of SLC22A24 in publicly available databases (which either average expression levels from multiple samples or report results of pooled samples) may be due to the high allele frequency of the rs11231341 encoding the p. Tyr501Ter. Surprisingly, the premature stop codon has not been found in primates[71] (61 chimpanzee, 10 bonobo, 43 gorilla, 9 orangutan). However, according to the three ancient human genomes, the Altai Neandertal, Denisova, Ust-Ishim and Vindija, the ancient humans were either p. Tyr501Ter homozygous or heterozygous (available from the ancient genome browser, https: //bioinf. eva. mpg. de/jbrowse/) [72,73]. These data suggest that the mutation was introduced in the ancient human period, the reason for which remains an open evolutionary question. Examination of GWAS and publicly available databases (GWAS Catalog, NCBI Phenotype-Genotype Integrator) revealed strong associations between SNPs in SLC22A24 and plasma levels of various metabolites, particularly those of steroid glucuronide conjugates (S1 Table), as well as steroid sulfate conjugates (S1 Table[25]). SLC22A24 p. Tyr501Ter (rs11231341), which has no transport activity and no protein expression on the plasma membrane (Fig 6), is associated with lower plasma levels of steroid glucuronides in three independent cohorts and in multiple ethnic groups (Table 1). Thus, it is reasonable to speculate that individuals harboring p. Tyr501Ter would have reduced plasma steroid glucuronide levels due to their reduced ability to reabsorb these metabolites. Interestingly, we observed that SLC22A24 possesses a PDZ-consensus motif at its C-terminal, which is also present in several known transporters localized to the apical membrane of the renal proximal tubule [74,75] (S11 Table). The presence of this motif supports the direction of the observed associations and the idea that the transporter functions in the reabsorption of steroid conjugates in the kidney. Although it has been shown that the ABC transporters in the proximal tubule, MRP2 and MRP3 function in the efflux of a steroid conjugates into the urine and plasma, respectively[76], to our knowledge, there have been no reports characterizing renal reabsorptive SLC transporters for steroid glucuronide conjugates. Glucuronide conjugates of steroids normally undergo net secretion in the proximal tubule, presumably by MRP2 and the organic anion transporters, OAT1 and OAT3 [76]. Though our data suggest that SLC22A24 functions in the reabsorption of steroid metabolites in the kidney, future studies are needed to confirm its role. In particular, measurements of steroid metabolites in both urine and plasma are required to understand the role of the transporter in their renal clearance. Unfortunately, urinary levels of steroid conjugates were not available in ARIC, which was used as our discovery cohort. The highly significant association between the SLC22A24 nonsense variant and androsterone glucuronide levels led us to examine associations between the variant and diseases that are known to be associated with this metabolite. Through a phenome-wide scan of multiple publicly available sources, we observed associations between SLC22A24 and conotruncal heart defect (p = 1x10-6) [77], lipid levels, and cardiovascular disease (p-values range from 1x10-5 to 9x10-5, data source Phenotype-Genotype Integrator, https: //www. ncbi. nlm. nih. gov/gap/phegeni). In addition, we used phenome-wide association study (PheWAS) approach to analyze the many phenotypes in UKBiobank (http: //geneatlas. roslin. ed. ac. uk/phewas/) with SLC22A24 SNPs that are associated with steroid and steroid conjugate levels, rs11231341 (p. Tyr501Ter) and rs78176967 (S12 Table). Hematological measurements (e. g. immature reticulocyte fraction, neutrophil percentage) are among the top traits that are significantly associated with the two SNPs (S12 Table). These traits have been previously associated with steroid hormones [78–81]. Further, studies have shown that levels of androsterone glucuronide are elevated in women with acne and/or hirsutism [82–87]. Through a detailed search of associations with acne and/or hirsutism, we noted that the top SNPs in the SLC22A24 locus associated with acne (p = 0. 001) in the UKBiobank[88] are among the top SNPs significantly associated with steroid and steroid glucuronide levels (S13 Table). Overall, the identified phenotypic data is consistent with the idea that dysregulation of steroid hormone metabolism contributes to the presentation of acne, blood traits, and cardiovascular disease in humans (S12 and S13 Tables). In conclusion, these studies represent the first functional characterization of SLC22A24, a transporter in the UST (Unknown Substrate Transporter) region of the genome. The transporter has a unique substrate specificity and our studies suggest that it functions in the reabsorption of steroid glucuronide conjugates in the kidney (Fig 7C). This work represents an important step in the global effort to functionally characterize the remaining members of the SLC22 family.
  Various public sources were used to obtain significant associations of SNPs within SLC22A24 gene +/- 50,000 kb (chr11: 62553988–62743269 (hg18); chr11: 62797412–62986693 (hg19); chr11: 63029940–63219221 (hg38) ) with clinical variables related to metabolites levels. These sources included the GWAS Catalog, Phenotype-Genotype Integrator, GRASPS, GWAS Metabolic Server (http: //metabolomics. gwas. eu) and others. The results from the search in public sources are shown in S1 Table. An application was approved by the ARIC Publication Committee to determine the associations of SLC22A24 variants with steroid and bile acid metabolites in ARIC cohort (Manuscript proposal #3167). Below we described the ARIC study population used in this association analyses, metabolite measurement and association analyses of selected SNPs and metabolites relevant to this study. Study population: The ARIC is a prospective epidemiologic study conducted in U. S. , designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date[89]. Using this cohort, investigators have published several papers related to associations between serum metabolome and diseases or traits among the subjects in the ARIC study[90]. In general, each visit included interviews and a physical examination [89]. In 2014, Metabolomic profiles were measured in baseline serum from 599 African- and 1,553 European-Americans. Participants were excluded if they did not give consent for use of DNA information. Assessment of Metabolomic Profiles: Methods for the assessment of metabolomics profiles, and whole exome sequencing were described previously [91–93]. In brief, metabolites were completed by Metabolon Inc. (Durham, USA) using an untargeted, gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry (GC-MS and LC-MS) -based metabolomic quantification protocol. The annotated exome was captured by NimbleGen’s VCRome2. 1 (Roche NimbleGen), and the captured exons were sequenced using Illumina HiSeq 2000. A total of 573 African Americans and 1375 Caucasians were available for the association analyses. The primary analysis was to determine the association of rs11231341 (SLC22A24 p. Tyr501Ter) with androsterone glucuronide (X-22379) and etiocholanolone glucuronide. Yousri NA et al. have published the whole exome sequencing to identify genetic polymorphisms associated with metabolite levels in Middle Eastern population[9]. Using the data computed from Yousri NA et al. [9], the beta and p-value for the association of SLC22A24 p. Tyr501Ter (rs11231341) with androsterone glucuronide (X-22379) and etiocholanolone glucuronide are shown in Table 1. Human embryonic kidney cell lines (HEK293) containing a Flp-In expression vector (HEK293 Flp-In) were used to create either transient or stable cell lines expressing SLC22A24 cDNA or vector only DNA. SLC22A24 (NM_173586 and NM_001136506) tagged open reading frame (ORF) clone and vector control (pCMV6-Entry) were purchased from OriGene. These vectors were either transiently transfected or stably transfected into Flp-In 293 cells using Lipofectamine LTX (Thermo Fisher Scientific). 500 ng of DNA and 1 μL of Lipofectamine LTX or 10 μg of DNA and 44 μL of Lipofectamine LTX were used for transfection into each well of the 24-well plate (seeding density 2. 0x105 cells/well) or 100 mm tissue culture plate (seeding density 4x106 cells/well) respectively. More detailed methods to create stably or transiently transfected cells have been described from our groups (see [26,38,94]). For transient transfection, after 36 to 48 hours, cells were use for transporter studies (see section called Transporter uptake studies) or for protein quantifications (see section called Analysis of SLC22A24 protein levels in transiently expressing HEK293 cells.). For stable cell lines, after 48 hours, cells were transferred to a new 100 tissue culture plate and were treated with 500 μg/mL Geneticin. Fresh media containing 500 μg/mL Geneticin was replaced each day. For the cloning, pooled total RNA of human kidney and liver were purchased from Clontech. Total RNA (2 μg) from each sample was reverse transcribed into cDNA using SuperScript VILO cDNA Synthesis kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. For the expression profiling of SLC22A24, the cDNA from pooled human tissues was purchased from Takara Bio Inc. In particular the cDNA from two tissue panels was purchased, Human MTC Panel I and II. S7 Table shows the primers that were used in the PCR to clone the transcripts, NM_173586 and NM_001136506. PCR products were cloned into pcDNA5FRT and sequenced (MCLAB, South San Francisco) to confirm the transcript. In addition, the primers that were used in the PCR to detect the presence of GAPDH (housekeeping gene) and the three SLC22A24 isoforms are shown in S7 Table. For expression profiling study, 10 ng cDNA of various tissues (Takara Human MTC panel I & II) were used for each reaction and amplified by KOD Xtreme Hot Start DNA polymerase kit (Takara). The PCR cycling conditions used are: (i) activation at 94°C for 2 min, (ii) denature at 98°C for 10 sec, (iii) annealing at 57. 5°C for 30 sec and (iv) extension at 68°C for 1 min. HEK293 Flp-In cells were grown in 24-well poly-D-lysine coated plates (seeding density of 1. 5–1. 8 x105/well) until 75–80% confluency. Upon reaching confluency, cells were transiently transfected with vector only or vector containing different SLC22A24 isoforms (in pCMV6-Entry expression vector). The different isoforms were: SLC22A24 with 552 amino acids (NM_001136506. 2, ENST00000612278. 4), SLC22A24-551 with 551 amino acids (NM_001136506. 2, ENST00000417740. 5) and SLC22A24-322 with 322 amino acids (NM_173586. 2) and SLC22A24 p. Tyr501Ter (c. 1503T>G) (in both pCMV6-Entry and pcDNA5FRT vector backbone). 500 ng of the plasmid DNA, 1 μL of Lipofectamine LTX (Thermo Fisher Scientific) and 100 μL of the Opti-MEM I reduced serum media (Thermo Fisher Scientific) were used in the transfection mixture. 40 hours after transfection, media was removed and 350 μL of RNA Lysis buffer was added to each well. Total RNA was isolated using the Qiagen RNeasy kit (Qiagen). cDNA was synthesized using SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Quantitative RT-PCR (qRT-PCR) was performed using Taqman reagents and specific primer and probe sets for human SLC22A24 (Assay ID: Hs00543210_m) and GAPDH (Assay ID: Hs99999905_m1) (Applied Biosystems, Foster City, CA). Reactions were performed in a 96-well plate with a 10 μL reaction volume using an ABI 7900HT Fast Real-time PCR system (Applied Biosystems) using the default instrument settings. Expression levels were determined from three independent biological samples using the Ct method after normalization to endogenous levels of GAPDH[56,95]. The results are expressed as a fold increase of the SLC22A24 mRNA level over the cell lines expressing the vector control. Sequences of SLC22A24 orthologs from mouse lemur (Microcebus murinus, Transcript ID ENSMICT00000042921. 1), rabbit (Oryctolagus cuniculus, XM_002720992. 3, Transcript ID ENSOCUT00000010486. 2), and horse (Equus caballus, Transcript ID ENSECAT00000014835. 1) were obtained from ensembl. org (release 95) [45] and the National Center for Biotechnology Information (NCBI). The cDNA of the gene was synthesized by GeneScript and inserted into the BamHI and XhoI restriction sites on the expression vector pcDNA5FRT (Invitrogen). The cDNA of the rat Slc22a9/Slc22a24 (NM_173302. 1) was purchased from OriGene (Catalog number: RR202601). The synthesized SLC22A24 ortholog cDNA clones were used to make GFP fusion constructs to determine their subcellular localization. The GFP coding sequence was ligated to the 3’ end of the SLC22A24 ortholog cDNA in the expression vector pcDNA5/FRT using In-Fusion HD cloning kit (ClonTech #639642). The human SLC22A24 GFP fusion construct was purchased from OriGene (Catalog number: RG227944). The primers used to clone the GFP fusion constructs for the other non-human species are shown in S9 Table. The sequence of the constructs was confirmed by sequencing (MCLAB, South San Francisco). HEK293 Flp-In cells stably or transiently transfected with SLC22A24 were seeded at a density of 180,000 to 200,000 cells/0. 5 mL in poly-D-lysine 24-well plates approximately 16 to 24 hours prior to uptake studies. For uptake studies in transiently expressing SLC22A24, methods described in previous section were performed before this study. Before the uptake studies, the culture medium (Dulbecco’s modified Eagle’s medium, DMEM H-21, supplemented with 10% fetal bovine serum) was removed and cells were incubated in 1. 0 mL HBSS for 10–20 min at 37 °C. For the screening of radiolabeled compounds as substrate of SLC22A24, trace amount of the radiolabeled compounds (3H or 14C) were diluted in the HBSS (1: 2000 or 1: 3000) for uptake experiments. The details of the compound concentrations and uptake time are described in the results or figure legends. Uptake reactions were terminated by washing cells twice with 1 mL HBSS buffer and the cells were incubated in 700–800 μL of lysis buffer (0. 1 N NaOH, 0. 1% v/v SDS) and then 650–750 μL of cell lysate was transferred to scintillation fluid for scintillation counting. Experimental condition used in this study was similar to transporter assays published previously by our group[95,96]. For pH dependence experiments, HBSS buffer was adjusted to different pHs (5. 5,7. 4 and 8. 5) by adding hydrochloric acid or sodium hydroxide[38]. For chloride dependence study, two different uptake buffers were used: (1) chloride free buffer (125 mM sodium gluconate, 4. 8 mM potassium gluconate, 1. 2 mM magnesium sulfate, 1. 3 mM calcium gluconate, and 5 mM HEPES; adjusted with sodium hydroxide to pH 7. 4); or (2) sodium buffer (125 mM sodium chloride, 4. 8 mM potassium chloride, 1. 3 mM calcium chloride, 1. 3 mM magnesium sulfate, and 5 mM HEPES, adjusted with sodium hydroxide to pH 7. 4) [95,97]. For trans-stimulation studies, experimental conditions described in our previously published methods were used[38]. In brief, the SLC22A24 or EV stable cell lines were pre-incubated with either buffer or 2 mM succinic acid, 2 mM α-ketoglutaric acid or 2 mM glutaric acid for 2 hours. Then, the cells were washed twice with HBSS before initiating uptake of the anions (estrone sulfate, estradiol glucuronide, androstanediol glucuronide or taurocholic acid). We characterized the kinetics of the three steroid conjugates and two bile acids by SLC22A24, discovered from the initial screening. We selected SLC22A8 for comparison to SLC22A24 due to the significant accumulation of steroid conjugates by SLC22A8. The kinetic studies were performed following methods developed in our group[38]. In brief, these studies were performed using stable cell lines expressing SLC22A24 (NM_001136506) or SLC22A8[98]. For the kinetic studies of bile acid, only SLC22A24 expressing cells were used, as bile acids are poor substrates of human SLC22A8[99]. For each substrate, we varied the concentrations of the unlabeled compounds. The uptake rate was evaluated at 1 minute, as this fell within the linear range in the uptake versus time plot for each substrate. Each point represents the mean ± SD uptake in the transporter-transfected cells minus that in empty vector cells. The plots show the result for a representative experiment of n = 2. HEK293 Flp-In cells stably transfected with SLC22A24 (NM_001136506) were seeded at a density of 200,000 to 220,000 cells/0. 5 mL in poly-D-lysine 24-well plates approximately 16 to 24 hours prior to the experiments. On the day of the experiments, cells were washed with 1 mL of Hank’s buffered salt solution (HBSS) per well and then preincubated for 10–20 min in the 1 mL of HBSS buffer. To assess inhibition, the cells were incubated with uptake buffer (1 μM unlabeled taurocholic acid and trace amount of [3H]-taurocholic acid in HBSS) containing either 100 μM estrone sulfate as positive control, 1% DMSO as negative control or 100 μM of the selected test compounds. Each of the 24-well plates contained negative and positive controls. Uptake of [3H]-taurocholic acid was stopped after 10 min by washing twice with ice-cold HBSS. The cells were lysed in 900 μL of lysis buffer (0. 1 N NaOH and 0. 1% SDS in double distilled water) per well while shaking for up to 90 min. 820 μL of the lysate was then added to 2. 5 mL of EcoLite scintillation fluid (MP Bio), and the radioactivity was determined on a LS6500 Scintillation Counter (Beckman Coulter). Values were corrected for protein concentration as determined with a BCA assay kit (Thermo Scientific, Rockford, IL). All values were determined in triplicate, and final values are expressed as % uptake relative to negative control (1% DMSO). Methods used in the inhibition studies were from previous studies in our laboratory [100,101]. The test compounds were tested at least one time and some compounds were selected to test two or three times to check for consistent results. A 100 mm tissue culture plate of HEK293 Flp-In cells was transiently transfected with the following expression vectors: vector only (pCMV6-Entry), SLC22A24 (NM_001136506), SLC22A24-322 (NM_173586), SLC22A24 p. Tyr501Ter (created using site directed mutagenesis). All proteins contained a C-terminal Myc-DDK tag. For evaluation of the SLC22A24 protein levels, cell lysates were collected 48 hours after transfection. Plasma membranes were separated from intracellular membrane using the Plasma Membrane Protein Extraction Kit (Abcam ab65400) [32]. Transfected cells were harvested in 2 mL of homogenization buffer. Cells were homogenized using the syringe-based homogenization method. A needle (27 gauge) was attached to a 1 mL syringe. The cells lysates were passed through the syringe 5 times. A higher gauge needle, 30 gauge, was then used and the suspension was passed through for 5 additional times. The plasma membrane fraction was resuspended in 50 μL lysis buffer. Cell samples were deglycosylated using PNGase F (NEB P0708L) per the manufacturer’s protocol. The resulting GFP fusion constructs were transiently transfected in human embryonic kidney 293 (HEK293) cells. The cells were maintained in Dulbecco' s modified Eagle' s Medium (DMEM) (Fisher) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and 10 mM HEPES (Fisher). Dr. R. Irannejad’s laboratory has established standard methods for transfecting HEK293 cells for membrane localization studies[102–104]. HEK293 cells were grown to ~70% confluence in poly-L-lysine coated glass coverslips in 12-well plates. The cells were transiently transfected with 1 μg plasmid DNA with 2 μL of Lipofectamine 2000 (Thermo Fisher Scientific). 24-hours after transient transfection, cells were fixed in 4% paraformaldehyde. Coverslips were mounted using ProLong Gold Antifade Mountant (Thermo Fisher Scientific) on glass microscope slides and visualized using Yokogawa CSU-22 Spining Disk Confocal microscope (Nikon Instruments, Inc). Samples of cell pellets from HEK293 Flp-In were prepared and sent to Metabolon Inc. (North Carolina, USA) for metabolites measurement using Metabolon platform. Cell pellet samples were prepared from five 100 mm culture dishes each of HEK293 Flp-In stably expressing vector only (pCMV6-Entry) or cells transiently expressing SLC22A24 cDNA (NM_001136506). 24 hours after transient transfection, media were removed and DMEM-H21, phenol red free, media (Invitrogen) containing 20% Fetal Bovine Serum, U. S. D. A. Approved Origin (Product Number 89510–186, Lot Number 356B16) were added to each dish. 48 hours after transient transfection, the cells were washed twice with cold PBS, and cells were scraped and transferred to a 15 mL falcon tubes. Tubes were centrifuged at 3000 rpm and supernatant were removed and stored the cell pellet in -80 °C freezer until shipping to Metabolon Inc. for metabolomics measurement (see[26] to obtain methods for metabolomic study). Raw metabolomic data were processed by Metabolon[105]. Individual metabolites were quantified and the values normalized. A two-tailed t-test was performed between EV and SLC22A24 and between EV and SLC22A1. False discovery rate (FDR) was used to correct the p-values. We eliminated potential false positive metabolites using the following criteria: if FDR < 0. 05 between SLC22A24 and EV cells, but p-value > 0. 05 between SLC22A1 and EV cells, the metabolites were considered false positives. The results of the analysis are included in S3 Table. Three phylogenetic trees were constructed. The first consists of the UniProt amino acid sequences for the human SLC22 family members with known substrates, human SLC22 members in the gene cluster between SLC22A8 and SLC22A9 of the human chromosome 11q12. 3 (hg19 assembly), and all identified mouse and rat SLC22 members (Fig 5A). The second and third tree were built focusing on anion transporters. The second tree (Fig 5B) includes the human SLC22A24, known SLC22A24 orthologs in other species identified in the UniProt, known human anion transporters in SLC22 family (SLC22A6, A7, A8, A9, A11 and A12), genes in the human chromosome 11q12. 3 (SLC22A10, A25), mouse anion transporters (Slc22a6, a7, a8, a9/a19, a9/a21, a12), mouse Slc22 genes in the clusters between Slc22a8 and Slc22a19 of the mouse chromosome 19qA (Slc22a26, a27, a28, a29, a30), rat anion transporters (Slc22a6, a7, a8, a9/a24, a12) and Slc22 genes in the clusters between Slc22a8 and Slc22a19 of the rat chromosome chr1q43 (Ust4r, Ust5r, Slc22a25). The third tree (S5 Fig) includes human SLC22A24 and the reference proteomes of all chordates (https: //www. uniprot. org/help/reference_proteome), which have sequence similarity to human SLC22A24 with an e-value < 1x10-200. For each tree, a multiple sequence alignment was created using MUSCLE[106], with default parameters on the CIPRES Science Gateway[107]. Phylogenetic trees were built using a RAxML[108] installation “RAxML-HPC2 on XSEDE” on the CIPRES Science Gateway. The tree was calculated on protein sequences using the protein GAMMA model with the JTT substitution matrix and rapid bootstrapping with 100 replicas. A resulting extended majority rule consensus tree was visualized using Dendroscope 3[109]. See S1 and S2 Appendices for the amino sequences used to create the phylogenetic tree in Fig 5A and 5B and S5 Fig. Due to the lack of available crystal structures, human OCT1 (SLC22A1), OCTN1 (SLC22A4), OAT1 (SLC22A6), and SLC22A24 were modeled using the crystal structure of the maltose-bound human GLUT3 (SLC2A3) in the outward-open conformation at 2. 6 Å as a template (PDB ID 4ZWC) [110]. The template was selected on the basis of the shared MFS fold assignment [10], structure quality, and sequence similarity to the targets of interest (40%, 38%, 39% sequence similarity to SLC22A1, SLC22A6, SLC22A24, respectively). The sequence alignment was obtained by a manual refinement of gaps in the output from the PROMALS3D server (S1A Fig) [111]. The maltose molecule from the crystal structure was treated as the BLK residue type in the alignment and was copied from the template structure into a model as a rigid body. One hundred models were generated for each protein using the “automodel” class of MODELLER 9. 16 (https: //salilab. org/modeller/). The models had acceptable normalized discrete optimized protein energy scores (zDOPE) [112,113]. The top scoring models were selected for electrostatic potential analysis with the APBS electrostatics plugin[114] within PyMOL 2. 0. 3 using the AMBER force field with default settings. We used the Gibson Assembly protocol from New England BioLabs (catalog no. E5510) to create the SLC22A24 p. Tyr501Ter construct by amplifying unique segments from the SLC22A24 wild type and pCMV6-Entry vectors. The following primers were used to amplify the segment containing SLC22A24 residues 1–500 from the SLC22A24 wild type plasmid: The following primers were used to amplify the segment containing the linker, tag, stop codon, and the rest of the vector backbone from the pCMV6-Entry vector: Each segment contains a 15 bp overhang necessary for the Gibson Assembly workflow. The amplified segments were then assembled following the manufacturer’s protocol (https: //www. neb. com/protocols/2012/12/11/gibson-assembly-protocol-e5510). Frozen human postmortem frozen renal cortical tissues from donors aged 3 to 29 years old were obtained from the NIH NeuroBioBank at the University of Maryland, Baltimore, MD[115,116]. These tissues were selected from patients, who are of self-reported African American descent. Tissues were procured at the time of autopsy within 48 hours after death and were kept frozen at -80°C for later research. Tissues were selected for having no renal abnormalities in pathology and primary diagnosis. Twenty kidney samples were selected for quantitative proteomic analysis (see section below). Genomic DNA from the 20 renal cortical tissues procured from the NIH NeuroBioBank were isolated using Wizard genomic DNA purification kit (Promega). The following forward (CCACAAGGGCAGAAAGTATG) and reverse primers (CAAATTATCAAAGCTGCGGGTTA) were used to PCR the genomic region of SLC22A24 and using Sanger sequencing primer (TAAGCCAGATATTGTTCACG) to determine the genotype for the stop-gained variant in SLC22A24, c. 1503T>G (rs11231341). Absolute quantitative proteomics was performed on the 20 renal cortical tissues. SLC22A24 and SLC22A24-551 were quantified using LC-MS/MS with Selective Reaction Monitoring (SRM) approach by Omics Technologies, Inc. (http: //www. proteomics. omicstech. com/proteomics/srm. html, previously known as MyOmicsDx, Inc. , Towson, MD, USA). The following are the main steps for quantitative proteomic analysis for the two transcript isoforms of SLC22A24. The detailed material and method used for each steps are described below as well as in our previous submitted manuscript[116]. The material and methods described below were provided by Omics Technologies, Inc.
summary: Steroid hormones, ranging from sex steroids such as testosterone to glucocorticoids play key roles in human health and disease. Accordingly, the identification of the genes and proteins involved in their synthesis, disposition and elimination has been the subject of numerous genetic studies. We have been intrigued by recent studies demonstrating that genetic variants in or near a gene encoding SLC22A24 are strongly associated with steroid levels. SLC22A24 is an orphan transporter with no known ligands and no known biological functions. In this study, we use cellular and computational methods to show that SLC22A24 transports steroid conjugates, bile acids, and other dicarboxylic acids. Based on the direction of association of a common stop codon in SLC22A24 with lower levels of steroids, our studies suggest that the transporter functions to reabsorb steroid conjugates in the kidney, a surprising finding, given that conjugation pathways generally function to create polar molecules that are readily eliminated by the kidney. The absence of the transporter gene in many species and its presence in higher order primates both suggest that SLC22A24 plays a specialized role in steroid homeostasis. Overall, our studies indicate that SLC22A24 functions in the reabsorption of conjugated steroids in the kidney.
keywords: genome-wide association studies
  medicine and health sciences
  chemical compounds
  ions
  anions
  salts
  organic compounds
  membrane proteins
  metabolomics
  steroids
  genome analysis
  pharmacology
  kidneys
  cellular structures and organelles
  drug metabolism
  physical chemistry
  genomics
  sulfates
  chemistry
  cell membranes
  pharmacokinetics
  biochemistry
  organic chemistry
  anatomy
  cell biology
  genetics
  biology and life sciences
  physical sciences
  renal system
  metabolism
  computational biology
  human genetics
title: Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies